XML 41 R45.htm IDEA: XBRL DOCUMENT v2.4.0.8
Debt - Additional Information (Detail) (USD $)
In Millions, unless otherwise specified
 0 Months Ended 6 Months Ended 6 Months Ended 6 Months Ended
Jun. 30, 2014
Loan and Security Agreement
Jun. 30, 2014
Loan and Security Agreement
Tranche
Jun. 30, 2014
Loan and Security Agreement
Securities Pledged as Collateral
Jun. 30, 2014
Revolving Credit Facility
May 31, 2014
Revolving Credit Facility
Jun. 30, 2014
First Tranche (Term Loan A)
Loan and Security Agreement
Jun. 30, 2014
Second Tranche (Term Loan B)
Loan and Security Agreement
Jun. 30, 2014
Third Tranche (Term Loan C)
Loan and Security Agreement
Line of Credit Facility [Line Items]                
Maximum borrowing limit   $ 30.0   $ 7.0        
Term of agreement   5 years            
Number of loan tranches   3            
Loan and security agreement           10.0 10.0 10.0
Borrowing conditions             The second tranche of $10.0 million (“Term Loan B”) is contingent upon the approval, if it occurs, by the U.S. Food and Drug Administration (“FDA”) of the Company’s premarket approval application for either the plasma or platelet system (the “PMA Approval”). The availability of Term Loan B expires at the earlier of (i) six months after receiving PMA Approval or (ii) June 30, 2015. The third tranche of $10.0 million (“Term Loan C”) will be available from July 1, 2015 through December 31, 2015, contingent upon both (i) obtaining PMA Approval and (ii) the Company achieving trailing six months’ revenue at a specified threshold (the “Revenue Event”).
Interest rate           6.95%    
Interest rate, description Term Loan A bears an interest rate of 6.95%. Term Loan B and Term Loan C will bear an interest rate calculated at the greater of 6.95% or 6.72% plus the three month U.S. LIBOR rate in effect three business days prior to the applicable Term Loan funding date.              
Maturity period Jun. 01, 2019     Jun. 30, 2014        
Principal and interest payments 42 months              
Final payment term percent 7.00%              
Terms of required periodic payments of interest and principal The Company is required to make interest only payments through December 2015 followed by forty-two months of equal principal and interest payments thereafter; however, if the Revenue Event is achieved no later than November 30, 2015, then the interest-only period may be extended through December 31, 2016, and the amortization period will be reduced to thirty months. The Company is also required to make a final payment equal to 7% of the principal amounts of the Term Loans drawn payable on the earlier to occur of maturity or prepayment.              
Commitment fee   0.2            
Lender legal fees 0.1              
Percentage of investments made in subsidiary     35.00%          
Outstanding amounts         $ 3.4